Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals Limited announced the completion of a significant share sale by its CEO, Dr. Christian Behrenbruch, and co-founder Dr. Andreas Kluge, each selling 2,000,000 shares at $29.50 per share through block trades. Both executives have agreed to a twelve-month lock-up on their remaining shares, indicating no immediate plans for further sales. This transaction reflects strategic financial management within the company, potentially impacting investor perceptions and market dynamics.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, with a portfolio targeting significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 39.99%
Average Trading Volume: 4,810
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.65B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.